Study of LJP 394 (Abetimus Sodium) in Lupus Patients
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
The primary purpose of this study is to assess the safety and pharmacodynamic effect of LJP
 394 at doses of 100 mg, 300 mg and 900 mg on anti-dsDNA antibody levels in patients with SLE.
STUDY NOW INCORPORATED INTO PHASE 3 STUDY NCT00089804.
Inclusion Criteria:

 -  Males or females between 12 and 70 years old.

 -  Diagnosis of Systemic Lupus Erythematosus (SLE)

 -  Females must be non-pregnant and non-lactating. Females must agree to use adequate
 birth control methods during the course of the study.

 -  Ability to have weekly intravenous (IV) administration of study drug.

 Exclusion Criteria:

 -  Prior exposure to abetimus sodium within 6 months prior to screening.

 -  Patients not on stable medications for 30 days prior to screening.

 -  Patients with acute or chronic infections.